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ABSTRACT. The purpose of this study was to evaluate the diagnostic ability of the
expanded gallbladder fossa and right posterior hepatic notch signs for hepatic fibrosis
determined by double contrast-enhanced MRI. For patients with chronic viral hepatitis
B (n596) or hepatitis C (n513) who underwent gadopentate dimeglumine-enhanced
dynamic MRI followed by ferucarbotran-enhanced gradient-echo imaging, the degree
of parenchymal fibrosis was categorised into three groups based on the extent of
reticulation and nodularity: (1) pre-cirrhotic or minimal fibrosis; (2) mild to moderate
fibrosis; (3) advanced cirrhosis. Each group was evaluated for the presence of a sharp
notch in the posterior–medial surface of the right lobe of the liver and expanded
gallbladder fossa. The expanded gallbladder fossa sign gradually increased with an
increasing degree of fibrosis (Group 1, 50%; Group 2, 61%; Group 3, 78%), and there
was no significant difference (p.0.5) between hepatitis B (67%) and C (73%). In the
case of the right posterior hepatic notch sign, only 6% of Group 1 and Group 2 patients
were positive; 27% of hepatitis B patients and 90% of hepatitis C patients in Group 3
exhibited the sign (p,0.05). Owing to its low prevalence, even in advanced cirrhosis,
the right posterior hepatic notch sign is of little value in the diagnosis of cirrhosis due
to chronic hepatitis B virus infection, whereas an expanded gallbladder fossa could be
used as a non-specific indicator of early fibrosis before the gross appearance of
advanced hepatic fibrosis.
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Among imaging landmarks related to the segmental
atrophy–hypertrophy complex and the secondary find-
ings of portal hypertension [1–5], the combination of an
expanded gallbladder fossa and the presence of a
posteromedial notch on the right lobe of the liver has
been suggested as a highly sensitive and specific sign
with which to differentiate cirrhotic from normal liver
[6, 7]. Particularly for chronic viral hepatitis, the early
recognition of cirrhotic change is essential for patients’
management of the cirrhosis itself and for monitoring the
development of hepatocellular carcinoma. However,
many of the previous reports mentioned only general
morphological changes of the liver, irrespective of the
histological grade or the cause of cirrhosis [1–7].
Recently, Aguirre et al [8] reported that double con-
trast-enhanced MRI (DC-MRI), including dynamic ima-
ging using gadolinium contrast agent and subsequent
delayed imaging following injection of superparamag-
netic iron oxide (SPIO) particles, was similar to histolo-
gical grading in scoring the hepatic fibrosis associated
with cirrhotic changes. The purpose of this study was to
evaluate the feasibility and usefulness of the expanded
gallbladder fossa and right posterior hepatic notch signs
in patients with viral-induced cirrhosis according to the
degree of hepatic fibrosis as determined by DC-MRI.
Methods and materials
Approval for this retrospective study was obtained
from our institutional review board, which waived the
requirement for informed consent for the review of
images. A retrospective search of electronic records for
those patients who underwent hepatic MRI during an 18
month period (from August 2005 to March 2007)
revealed 306 patients examined by DC-MRI.
After obtaining standard informed consent, MRI was
performed with a 3 T unit (Signa EXCITE; GE Medical
Systems, Milwaukee, WI). Fat-suppressed T2 weighted
fast spin echo images (repetition time/echo time (TR/
TE), 4000/98 ms; echo train length, 14) and double echo
chemical shift gradient-echo images (TR/first-echo TE,
second-echo TE, 160/2.4 ms (in-phase), 5.8 ms (opposed-
phase); flip angle, 70 ;˚ matrix, 352 6 300; slice thickness,
8 mm; interslice gap, 1.5 mm) were obtained before DC-
MRI. DC-MRI was performed using a three-dimensional
gradient-echo sequence (LAVA; GE Medical Systems,
Milwaukee, WI) using parallel imaging algorithms
(ASSET factor 2) in the axial plane (TR/TE, 3.5–4.2/1.0–
1.2 ms; flip angle, 10 ;˚ matrix, 320 6 256; slice thickness,
5 mm; slice spacing, 2.5 mm; number of slices, 64) during
a 16 s breath-holding period. A dynamic series consisted
of one pre-contrast series followed by three post-contrast
series, including arterial, portal and 5 min delayed phase
imaging, after administering a bolus injection of gado-
pentetate dimeglumine (0.1 mmol kg–1 Magnevist; Bayer
HealthCare Berlin, Germany) at a rate of 2 ml s–1. After
the dynamic imaging, SPIO (8 mmol kg–1 of Resovist;
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Bayer HealthCare) was administrated intravenously as
the second contrast agent. After 10 min, DC-MRI com-
prising T2 weighted fast spin echo and T1 weighted
double-echo-chemical-shift gradient-echo images were
obtained using the same parameters as those for pre-
contrast imaging.
A search through the medical records of 306 patients for
both viral antigen test and antibody titration results yielded
128 patients positive for hepatitis B antigen and 18 patients
positive for hepatitis C antibody. Digitally stored image
data from these 146 patients were retrieved and prelimi-
narily reviewed in conjunction with the medical records for
initial case selection by an attending radiologist with
12 years of experience in hepatic MRI. After exclusion of
those with a previous history of partial hepatectomy (n55)
or interventional treatment involving the left lobe or
posterior segment of the right lobe of the liver (n522)
and eight additional patients with focal lesions.2 cm near
the inferior portion of the left lobe or the posteromedial
portion of the right lobe of the liver, a total of 111 patients
(hepatitis B, n596; hepatitis C, n513; hepatitis B and C,
n52) remained. The two patients infected with both
hepatitis B and C were also excluded to further simplify
analysis, resulting in 109 patients enrolled: 84 men and 25
women aged 22–78 years (mean age: 54 years).
Image analysis
The right posterior notch sign was considered to be
present when there was a sharp indentation in the right
medial posterior surface of the liver, and the expanded
gallbladder fossa sign was considered present if the
gallbladder was bound medially by the edge of the
(a) (b)
Figure 1. A 46-year-old man with chronic viral hepatitis B categorised into Group 1 who was negative for the two
morphological signs. (a) Axial gradient-echo image (repetition time/echo time (TR/TE)5160/5.8 ms) shows fine reticulations
(arrowheads) at the peripheral portion of the liver parenchyma (reticulation score51) without any nodularity (nodularity
score50). (b) Right posterior hepatic margin is smoothly curvilinear without any notch sign (arrowheads), and the left side of the
gallbladder (asterisk) is partially abutting to the medial segment (arrow) on the axial contrast-enhanced three-dimensional
gradient-echo image (TR/TE54.2/1.2 ms). There were no portal hypertensive stigmata (not shown).
Figure 2. A 55-year-old woman with chronic viral hepatitis B
categorised into Group 2 who was positive for the expanded
gallbladder sign. Axial gradient-echo image (repetition time/
echo time (TR/TE)5160/5.8 ms) shows fine reticulations and
innumerable nodules in the entire liver parenchyma (reticu-
lation score52, nodularity score53); the inferior portion of
the lateral segment (arrow) is demonstrated on the same
plane as the gallbladder (asterisk) owing to the atrophy of
the medial segment. The right posterior hepatic notch was
not defined, and there were no portal hypertensive stigmata
(not shown).
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lateral segment of the left hepatic lobe below the
lowermost portion of the medial segment. The portal or
delayed phase images (2.5 mm slice thickness) from the
dynamic imaging were used to determine the presence of
the morphological signs by two independent readers —
one attending radiologist with 12 years of hepatic MRI
experience (Observer 1) and one junior resident
(Observer 2) in the radiology department.
The degree of hepatic fibrosis was determined on DC-
MRI by two attending radiologists with 14 years’ and
5 years’ experience with hepatic MRI according to the
liver texture score used by Aguirre et al [8] as follows:
1. Reticulation score: from 0 (reticulations not visible
on any section) to 4 (diffuse reticulations obvious on all
sections)
2. Nodularity score: from 0 (nodules not visible on any
section) to 4 (innumerable nodules obvious on all
sections).
Using the summated value of the reticulation and
nodularity scores (ranging from 0 to 8), each patient was
categorised into one of three groups: Group 1 (0–2, pre-
cirrhotic or minimal fibrosis); Group 2 (3–5, mild to
moderate fibrosis); and Group 3 (6–8, advanced cirrho-
sis) (Figures 1–4). The presence of portal hypertensive
stigmata (i.e. ascites, collateral veins and/or splenome-
galy) was also evaluated by the same radiologists.
Splenomegaly was considered present if the longest
splenic dimension was greater than 11 cm in any
direction [9–12].
Statistical analysis
The prevalence of both morphological signs in the two
populations of patients was compared using the
McNemar test, and weighted kappa (k) values for
interobserver variation were obtained. The likelihood
(a)
(c)
(b)
Figure 3. A 60-year-old man with chronic viral hepatitis B categorised into Group 3 who was positive for the two morphological
signs. (a) The entire liver parenchyma consists of thick fibrotic reticulations and macronodules, as seen on an axial gradient-echo
image (repetition time/echo time (TR/TE)5160/5.8 ms) (reticulation score54, nodularity score54). (b,c) The right posterior
hepatic notch (arrow) and expanded gallbladder fossa between the gallbladder (asterisk) and lateral segment (arrowheads) are
well demonstrated on the axial contrast-enhanced three-dimensional gradient-echo images (TR/TE54.2/1.2 ms). The spleen was
enlarged up to 16 cm (not shown).
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ratio test was performed for the linear trend between the
prevalence of each morphological sign with the degree of
fibrosis. x2 tests were used to evaluate the prevalence of
each morphological sign between the patients with and
without the imaging features of portal hypertensive
stigmata, and between the cirrhosis caused by hepatitis B
and hepatitis C.
Results
Among the 109 patients, the prevalence of right
posterior hepatic notch was much lower (p,0.001) than
that of expanded gallbladder fossa: 23 (21%) vs 74 (68%)
for Observer 1; 21 (19%) vs 73 (67%) for Observer 2. The
interobserver agreement was ‘‘excellent’’ for the pre-
sence of an expanded gallbladder fossa (k50.812),
whereas it was ‘‘good’’ for the presence of a right
posterior hepatic notch (k50.772).
The prevalence of the two morphological signs
increased with an increasing degree of cirrhotic change
(Table 1). The right posterior hepatic notch was demon-
strated in only 6% (3/50) of patients in Groups 1 and 2
but markedly increased (34%, Observer 1; 31%, Observer
2) in Group 3 (Figures 3 and 4), whereas the expanded
gallbladder fossa sign gradually increased with an
increasing degree of cirrhotic change (Figures 2 and 3)
(Table 1). In patients with portal hypertensive stigmata
(a) (b)
Figure 4. A 59-year-old man with chronic viral hepatitis C categorised into Group 3 who was positive for the right posterior
hepatic notch sign. (a) The entire liver parenchyma consists of fibrotic reticulations with variable thickness and micronodules, as
seen on an axial gradient-echo image (repetition time/echo time (TR/TE)5160/5.8 ms) (reticulation score54, nodularity score54).
The caudate lobe is relatively spared from the fibrotic changes and shows darker signal intensity (arrowheads) than the
remaining parenchyma. (b) The right posterior hepatic notch (arrow) is well defined on the axial contrast-enhanced three-
dimensional gradient-echo image (TR/TE 5 4.2/1.2 ms). The expanded gallbladder fossa sign was negative, and the spleen was
enlarged up to 13 cm (not shown).
Table 1. Prevalence of right posterior hepatic notch and expanded gallbladder fossa signs in patients with chronic viral
hepatitis according to the degree of hepatic fibrosis determined by DC-MRI (n5109)
Right Posterior hepatic notch (+) Expanded gallbladder fossa (+)
Hepatitis B (n596) Hepatitis C (n513) Hepatitis B (n596) Hepatitis C (n513)
Observer 1
Group 1 (n522) 1/21 (4.8%) 0/1 (0%) 10/21 (48%) 0/1 (0%)
Group 2 (n528) 0/21 (0%) 2/7 (29%) 11/21 (52%) 6/7 (86%)
Group 3 (n559) 15/54 (28%) 5/5 (100%) 43/54 (80%) 4/5 (80%)
p50.0009 p50.0021
Observer 2
Group 1 (n522) 1/21 (4.8%) 0/1 (0%) 12/21 (57%) 0/1 (0%)
Group 2 (n528) 0/21 (0%) 2/7 (29%) 11/21 (52%) 6/7 (86%)
Group 3 (n559) 14/54 (26%) 4/5 (80%) 41/54 (76%) 3/5 (60%)
p50.0021 p50.0635
Group 1 (pre-cirrhotic or minimal fibrosis), Group 2 (mild to moderate fibrosis) and Group 3 (advanced cirrhosis) patients are
subjectively determined by grading the reticulation and nodularity of the liver on double contrast material-enhanced MRI.
All of the p-values were calculated using the likelihood ratio test for linear trend in the overall data, regardless of the cause of
cirrhosis.
+ 5 presence of each morphological sign.
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(n582), the prevalence of both morphological signs was
significantly higher (p,0.05) than in other patients
(n527) (Table 2).
The prevalence of a right posterior hepatic notch was
significantly lower in patients with hepatitis B than in
those with hepatitis C (hepatitis B/C: 17/54% for
Observer 1 (p50.007); 16/46% for Observer 2
(p50.025)), whereas there was no significant difference
between hepatitis B and C for the prevalence of an
expanded gallbladder fossa (hepatitis B/C: 67/77% for
Observer 1 (p50.670); 67/69% for Observer 2 (p50.897)).
Discussion
Other than chronic ethanol abuse, which is the leading
cause of cirrhosis in Western countries, hepatitis B and C
are primary risk factors for cirrhosis and hepatocellular
carcinoma [13–16], and imaging recognition of virus-
induced cirrhosis might be more important for these
patients than for those with alcoholic cirrhosis [17]. The
cirrhotic change is a gradual and regional process, and
the correct diagnosis is not reliable without the whole
specimen of the explanted liver [18]. Although it has
limited value in determining the presence and severity of
cirrhotic change, percutaneous or laparascopic biopsy
has been used as the gold standard for evaluating the
degree of hepatic fibrosis in the entire liver [19]. In
addition, DC-MRI allows a feasible discrimination of the
fibrotic reticulations from the regenerating nodules in the
cirrhotic liver [8]. The delayed phase enhancement of
fibrotic reticulations by gadolinium contrast material is
well distinguished from the background parenchyma
consisting of regenerative nodules with decreased signal
intensity owing to SPIO uptake [8, 20, 21].
In the present study, the incidence of gallbladder fossa
expansion was similar to previous reports [6, 7];
however, the appearance of a right posterior notch was
limited. The low prevalence of a right posterior hepatic
notch in viral-induced cirrhosis compared with alcoholic
cirrhosis was highlighted by Okazaki et al [22]. In their
study, however, the prevalence of a right posterior
hepatic notch approximated 70%, even in patients with
viral-induced cirrhosis. Although their report contained
no comparative data between hepatitis B and C [22], we
found that hepatic fibrosis caused by hepatitis B showed
a significantly lower prevalence of the right posterior
hepatic notch than the changes caused by hepatitis C,
regardless of the degree of disease process.
The right posterior hepatic notch appears as if it
originated from a distortion of the liver surface at the
segmental border between the medially hypertrophied
caudate lobe and the atrophied right posterior segment
[7, 22]. Pathologically, macronodular cirrhosis is the
representative disease process for hepatitis B, whereas
the size of the cirrhotic nodule in hepatitis C is relatively
small (micronodular cirrhosis) [22, 23]. As it is unknown,
we may only speculate that there may be a different
mechanism resulting in an increased tendency for
caudate lobe hypertrophy and a right posterior hepatic
notch related to the micronodular cirrhosis [23]. During
the process of gradual and inherently non-uniform
hepatic fibrosis, thick septal fibrosis in patients with
micronodular cirrhosis would induce regional variation
in portal perfusion within the liver [24]. The different
perfusion gradients between the peripheral and central
portions of the liver would result in gross morphological
changes such as hypertrophy of the central portion,
including the caudate lobe, owing to the relatively higher
perfusion pressure. Macronodular cirrhosis, however,
consists of thin fibrotic septa and larger regenerating
nodules, and thus the regional variation in portal
perfusion would be negligible.
Expansion of gallbladder fossa is closely related to the
medial segment atrophy and other combined factors of
counterclockwise rotation of the liver [6]. As observed by
Rosenthal et al [25] using colour Doppler ultrasound,
flow in the portal venous branches to the lateral segment
and caudate lobe is uniformly hepatopetal, whereas the
medial segment often receives circular flow from the
right side of the umbilical segment with a lower amount
of blood than other segments. Even in early fibrosis,
which cannot be grossly depicted on MRI, overall portal
venous perfusion is usually reduced throughout the
entire liver, and the flow to the medial segment may
become more reduced to cause segmental atrophy. Thus,
it is not strange to observe the relatively higher
prevalence of expanded gallbladder fossa, even in
Group 1 and 2 patients, regardless of the cause of
cirrhosis, as in the present study.
This study has several limitations. Firstly, we did not
have a histological gold standard in this retrospective
study [26]. Even though more studies are needed to
confirm its ‘‘solid’’ validity, previously published MRI
Table 2. Prevalence of right posterior hepatic notch and expanded gallbladder fossa signs in patients with chronic viral
hepatitis according to the presence of portal hypertensive stigmata determined by MRI (n5109)
Right posterior hepatic notch (+) Expanded gallbladder fossa (+)
Observer 1
Portal hypertensive stigmata (2) (n527) 1 (3.7%) 11 (41%)
Portal hypertensive stigmata (+) (n582) 22 (27%) 63 (77%)
p50.0225 p50.0012
Observer 2
Portal hypertensive stigmata (2) (n527) 1 (3.7%) 10 (37%)
Portal hypertensive stigmata (+) (n582) 22 (27%) 64 (78%)
p50.0373 p50.0003
Portal hypertensive stigmata include ascites, collateral veins and splenomegaly.
All of the p-values were calculated using the x2 test.
+ 5 presence of each morphologic sign or portal hypertensive stigmata.
25 absence of portal hypertensive stigmata.
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grading [8] was used as a matter of convenience to
compare the prevalence of two morphological signs
related to the different degree of fibrosis defined on DC-
MRI. Secondly, despite using MRI, the size of cirrhotic
nodules, the thickness of the fibrotic reticulations and the
geographic distribution of the degree of the cirrhotic
changes were not quantitatively categorised in the
present study. A more organised access to the regional
distribution of hepatic fibrosis will be necessary to obtain
more sophisticated data for the relationship between the
morphological signs and substantial parenchymal
changes. Another limitation concerns the small size of
the cirrhosis caused by hepatitis C. The high prevalence
of the two morphological signs in patients consisting
mostly of those with cirrhosis from hepatitis C virus
infection has already been reported [7, 22]. Therefore,
despite the smaller number of hepatitis C patients, our
data showing the significantly low prevalence of the
right posterior hepatic notch sign in hepatic fibrosis
caused by hepatitis B compared with those from
hepatitis C seem to be valid.
In conclusion, using the degree of hepatic fibrosis
determined by DC-MRI as a reference standard, the
results of this study suggest that the right posterior
hepatic notch sign cannot be used as a tool to diagnose
early stage viral-induced cirrhosis. Patients with a
positive right posterior hepatic notch sign already
possessed the stigmata of portal hypertension, suggest-
ing an advanced disease process and bestowing very
little value upon this sign as a morphological marker to
predict early cirrhotic change of the liver. The right
posterior hepatic notch sign may be used as a reliable
tool in the diagnosis of advanced cirrhosis from hepatitis
C virus infection, but it has very limited value in patients
with hepatitis B virus infection owing to its low
prevalence, regardless of the degree of hepatic fibrosis.
The expanded gallbladder fossa sign, regardless of its
increasing prevalence with increasing severity of hepatic
fibrosis, could be a non-specific indicator of early fibrosis
before the gross appearance of advanced fibrosis
determined by DC-MRI in a number of patients.
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